Gene Therapy Market by Type (Gene silencing, Gene augmentation), Vector (Viral (Retroviral, AAV), Non-viral (Oligonucleotide)), Therapeutic Area (Neurology, Oncology), Delivery Method (In-vivo, Ex-vivo), RoA (Intravenous) & Region - Global Forecast to 202

Gene Therapy Market by Type (Gene silencing, Gene augmentation), Vector (Viral (Retroviral, AAV), Non-viral (Oligonucleotide)), Therapeutic Area (Neurology, Oncology), Delivery Method (In-vivo, Ex-vivo), RoA (Intravenous) & Region - Global Forecast to 2028

The gene therapy market is expected to reach USD 23.9 billion by 2028 from USD 9.0 billion in 2023, at a CAGR of 21.4% during the forecast period. The key factors driving the growth of the gene therapy market include increasing initiatives related to genomic research, and increasing number of regulatory approvals for gene therapy products. Moreover, growing demand for cell and gene therapies is an opportunity area for this market.

The gene therapy market has been segmented based on type, vector, therapeutic area, delivery method, route of administration and region.

“By therapeutic area, oncology segment accounted for the second largest share of the gene therapy market”

Based on type, the gene therapy market is categorized into neurology, oncology, hepatology, and other therapeutic areas.. In 2022, oncology accounted for the highest growth rate owing to factors such as The rising demand for targeted therapies (including gene therapy) against cancer, increasing cancer prevalence are the major factors driving the growth of this segment.

“By delivery method, the in vivo segment accounted for the largest share in the gene therapy market”

Based on end user, the gene therapy market is segmented into the gene therapy market is segmented into in vivo and ex vivo. In 2022, the in vivo segment accounted for a largest share of the gene therapy market. Growth in this market segment can be attributed to availability of many in vivo gene therapy products commercially and focus of research and development on this delivery method.

“North America: the largest share of the gene therapy market”

North America accounted for the largest share of the gene therapy market. The large share of the North America region can be attributed to major factors such presence of technologically advanced infrastructure in healthcare settings offering gene therapies, and easy accessibility to advanced therapeutics among others. Besides, the region has a well established healthcare system which further supports the growth of this market. Also, presence of some of the key players in the market is another key factor. Some examples of these players include Novartis AG (Switzerland), Biogen Inc. (US), Gilead Sciences, Inc. (US), Bristol-Myers Squibb (US), Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US) among others.

“Europe: The fastest-growing region in the gene therapy market.”

The Europe gene therapy market is projected to grow at the highest CAGR during the forecast period. This is attributed to one of the major factors including the growing initiatives for advancements of gene therapies, increasing prevalence of chronic diseases and support offered by the government organizations for developing advanced targeted therapies.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 70% and Demand Side 30%

By Designation: Managers - 45%, Directors- 30%, and Executives - 25%

By Country: North America- 25%, Europe- 25%, Asia Pacific- 40%, Latin America- 5%, and Middle East- 3% & Africa- 2%

Prominent Players

Novartis AG (Switzerland)

Biogen Inc. (US)

Gilead Sciences, Inc. (US)

Bristol-Myers Squibb (US)

Alnylam Pharmaceuticals, Inc. (US)

Sarepta Therapeutics, Inc. (US)

Amgen, Inc. (US)

Orchard Therapeutics Plc (UK)

F. Hoffmann-La Roche Ltd. (Switzerland)

Jazz Pharmaceuticals Plc (Ireland)

uniQure N.V. (Netherlands)

Johnson & Johnson (US)

Bluebird Bio, Inc. (US)

BioMarin Pharmaceutical Inc. (US)

Krystal Biotech, Inc. (US)

Shanghai Sunway Biotech Co. Ltd. (China)

SIBIONO GeneTech Co. Ltd. (China)

Ferring B.V. (Switzerland)

Vertex Pharmaceuticals Incorporated (US)

Pfizer, Inc. (US)

Sangamo Therapeutics, Inc. (US)

REGENXBIO (US)

Ultragenyx Pharmaceutical Inc. (US)

MeiraGTx Holdings Plc (US)

AnGes, Inc. (Japan)

Research Coverage:

This report provides a detailed picture of the gene therapy market. It aims at estimating the size and future growth potential of the market across different segments, such as the type, indication, end user and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the gene therapy market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

The report provide insights on the following pointers”

Analysis of key drivers (growth in regulatory approvals for gene therapy products), opportunities (cell and gene therapy demand), restraint (budget constraints) and challenges (challenges associated with supply chain) influencing the growth of the gene therapy market.

Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the gene therapy market.

Market Development: Comprehensive information about lucrative markets- the report analyses the gene therapy market across varied regions.

Market Diversification: Exhaustive information about new products and service, untapped geographies, recent developments, and investments in the gene therapy market.

Analysis of clinical pipeline data and data on products estimated to be launched during the forecast period.

Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like Novartis AG (Switzerland), Biogen Inc. (US), Gilead Sciences, Inc. (US), Bristol-Myers Squibb (US), Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), Amgen, Inc. (US), Orchard Therapeutics Plc (UK), F. Hoffmann-La Roche Ltd. (Switzerland), among others in the gene therapy market.